BidaskClub upgraded shares of Quotient (NASDAQ:QTNT) from a hold rating to a buy rating in a research note published on Thursday, May 31st.

Several other equities research analysts have also commented on QTNT. ValuEngine raised shares of Quotient from a strong sell rating to a sell rating in a research note on Tuesday, May 29th. BTIG Research set a $10.00 target price on shares of Quotient and gave the stock a buy rating in a research note on Sunday, May 20th. Finally, Zacks Investment Research upgraded shares of Quotient from a sell rating to a hold rating in a research note on Wednesday, April 11th. Two research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. Quotient presently has an average rating of Hold and an average target price of $11.50.

NASDAQ:QTNT traded down $0.02 during mid-day trading on Thursday, hitting $6.66. 316,400 shares of the company’s stock were exchanged, compared to its average volume of 483,469. Quotient has a one year low of $2.78 and a one year high of $7.67. The company has a debt-to-equity ratio of -5.94, a current ratio of 1.92 and a quick ratio of 1.32. The firm has a market capitalization of $325.46 million, a P/E ratio of -3.28 and a beta of 0.25.

Quotient (NASDAQ:QTNT) last posted its quarterly earnings data on Tuesday, May 29th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.04. The business had revenue of $6.14 million for the quarter, compared to the consensus estimate of $5.60 million. equities research analysts expect that Quotient will post -1.55 earnings per share for the current fiscal year.

In other news, major shareholder Life Sciences Maste Perceptive bought 450,000 shares of the company’s stock in a transaction dated Wednesday, May 23rd. The shares were purchased at an average price of $6.45 per share, for a total transaction of $2,902,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 29.00% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC raised its holdings in shares of Quotient by 61.9% during the fourth quarter. Perceptive Advisors LLC now owns 6,033,020 shares of the company’s stock valued at $29,683,000 after purchasing an additional 2,306,034 shares during the last quarter. Park West Asset Management LLC raised its holdings in shares of Quotient by 11.1% during the fourth quarter. Park West Asset Management LLC now owns 300,087 shares of the company’s stock valued at $1,485,000 after purchasing an additional 30,053 shares during the last quarter. Hudson Bay Capital Management LP raised its holdings in shares of Quotient by 966.7% during the fourth quarter. Hudson Bay Capital Management LP now owns 480,000 shares of the company’s stock valued at $2,376,000 after purchasing an additional 435,000 shares during the last quarter. Tekla Capital Management LLC raised its holdings in shares of Quotient by 76.3% during the fourth quarter. Tekla Capital Management LLC now owns 209,519 shares of the company’s stock valued at $1,037,000 after purchasing an additional 90,658 shares during the last quarter. Finally, Prosight Management LP purchased a new position in shares of Quotient during the fourth quarter valued at approximately $4,616,000. 61.47% of the stock is owned by hedge funds and other institutional investors.

Quotient Company Profile

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.